The GVL effect following allo-SCT is one of the most prominent examples showing the ability of the immune system to eliminate malignant hematological diseases. Tumor-associated Ags (TAA), for instance WT1 and proteinase-3, have been proposed as targets for T cells to establish a GVL effect. Here, we examined an additional TAA (MUC1) as a possible T-cell target of GVL-related immune responses. We have defined new peptide epitopes from the MUC1 Ag to broaden patients' screening and to expand the repertoire of immunologic monitoring as well as for therapeutic approaches in the future. Twenty-eight patients after allo-SCT have been screened for T-cell responses toward TAA (proteinase-3, WT1, MUC1). We could detect a significant relationship between relapse and the absence of a TAA-specific T-cell response, whereby only 2/13 (15%) patients with TAA-specific CTL relapsed, in contrast to 9/15 (60%) patients without TAA-specific CTL responses (Po0.05). In conclusion, CD8 þ T-cell responses directed to TAA might contribute to the GVL effect. These observations highlight both the importance and the potential of immunotherapeutic approaches after allo-SCT.
Introduction
The GVL effect after allo-SCT shows the ability of the immune system to eradicate malignant cells. However, this mechanism seemed to be a strictly clinically described phenomenon. The correlation between clinical outcome and the detection of T-cell responses against certain tumorspecific or tumor-associated Ags (TAA) is controversially discussed.
A variety of TAA were found to be immunogenic with the capability to induce CD8 þ T-cell responses. The most common Ags found to be possible targets of a specific GVL effect are proteinase-3 and WT1. 1, 2 Others include mHAs such as HA-1 and HA-2 3 as well as neo Ags evolving from chromosomal rearrangements, namely BCR-ABL. 4 It was hypothesized that the emergence of the specific T cells targeting Ags overexpressed in hematopoietic malignancies correlate with a better relapse-free survival after allo-SCT. 1, 5 In our study, we extended the screening for CTL responses targeting MUC1 Ag as TAA. MUC1 is a transmembrane type I glycoprotein comprising a unique extracellular domain containing 20-60 tandem repeat domains. 6 The MUC1 (CD227) Ag is overexpressed in a variety of malignancies 7, 8 with its ability to elicit Ag-specific T-cell responses in vivo after vaccination with MUC1 peptide-pulsed DC. 9 The rationale to consider MUC1 Ag as a potential target of a GVL effect is based on the fact that MUC1 is also overexpressed in hematopoietic disorders such as AML and multiple myeloma (MM). 8 So far, only two HLA-A*0201-9-mer peptides from this Ag have been defined that are capable of eliciting a peptidespecific CTL response. 10 We extended the MUC1 epitope search using the 'reverse immunology' method 11 provided by the SYFPEITHI software (http://www.syfpeithi.de) and confirmed its immune relevance with the detection of epitope-specific IFN-g secretion by intracellular cytokine staining.
By investigating these extended CTL responses against a total of three different TAA in AML, ALL and MM, a better and more accurate way of screening a larger cohort of patient's post allo-SCT is made possible. This also provides the basis for peptide-based vaccination procedures in cancer patients.
Patients, materials and methods

Patients
Twenty-eight patients who underwent allo-SCT with different hematological malignancies were recruited. We studied the specific T-cell responses against three TAA, namely MUC1, WT1 and proteinase-3, respectively.
All patients were expected to show a high expression toward one of these TAA mentioned above, and expressed at least one of the following HLA molecules: HLA-A*0201, HLA-A*6801, HLA-B*0702 or HLA-B*4402. The study was approved by the institutional review board, and blood draws were performed only after obtaining informed consent. Patient characteristics are shown in Table 1 . The underlying diseases were categorized according to risk stratification as described earlier: [12] [13] [14] Patients received either a myeloablative regimen comprising the standard protocols (TBI/CY or BU/CY) or reduced-intensity conditioning (see footnote in Table 1 ).
Peptides
The MUC1 protein sequence was screened with HLA class I binding algorithms provided by the SYFPEITHI software as described earlier 15, 16 , and new MUC1 peptides binding to HLA-A*6801, HLA-B*0702 and HLA-B*4402 were predicted. The peptides (Table 2) were synthesized using standard fluorenylmethoxycarbonyl chemistry on an automated peptide synthesizer (432A; Applied Biosystems, Weiterstadt, Germany). Synthesis products were analyzed by reverse-phase high-performance liquid chromatography (HPLC; Varian Star; Zinsser, Munich, Germany) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for quality control (G2025A, HewlettPackard, Palo Alto, CA, USA). Peptides with a purity of less than 80% were purified using preparative HPLC.
Preparation of PBMCs and generation of DCs
Peripheral blood mononuclear cells were isolated by using Ficoll-Paque density-gradient centrifugation of heparinized blood obtained either from healthy volunteers or from patients. The generation of monocyte-derived DC from PBMC was performed as described earlier. 10, 17, 18 Induction of MUC1-specific cytotoxic T lymphocytes in healthy individuals Monocyte-derived mature DCs (5 Â 10 5 /ml) were pulsed with 10 mg/ml peptide and incubated with 3 Â 10 6 autologous CD8 þ T cells that were enriched by positive selection with CD8 microbeads (Miltenyi, Bergisch-Gladbach, Germany) according to the manufacturer's guidelines in 24-well plates (Greiner, Solingen, Germany) in 2 ml RPMI 1640/10% heat-inactivated fetal calf serum and 100 mg/ml gentamicin. On day 5, 20 U/ml human recombinant IL-2 (Proleukin, Chiron, USA) were added. Cells were harvested and re-stimulated with irradiated (30 Gy) autologous peptide-pulsed PBMC on day 7; IL-2 was added at a concentration of 20 U/ml every other day. After 2-3 weekly re-stimulations, cells were analyzed for peptide-specific response on the basis of detection of intracellular IFN-g secretion using flow cytometry following specific stimulation with respective peptides.
Cell surface and intracellular cytokine staining Intracellular cytokine staining for IFN-g was performed as described earlier. 16 Stimulation was considered to be positive if the difference between the peptide-specific stimulation and the negative control exceeded 0.1% of all CD3 þ /CD8 þ T cells 19 with at least 250 000 living cells to be enumerated. To analyze the generated CTL lines, IFN-g assay was performed either with peptide-loaded autologous DC or with primary tumor cells as stimulators at the ratio of 5:1 (CTL: DC/tumor cells). Blocking of the MHC class I Ag recognition pathway was performed by a 1 h incubation of the tumor cells with the MHC class I Ab W6/32.
Cell staining with MHC-peptide pentameric complexes PBMCs (5 Â 10 5 -1 Â 10 6 ) were stained with 10 ml PElabeled HLA-A*0201 or HLA-A*6801 pentamers (ProImmune, Oxford, UK) according to the manufacturer's guidelines.
Detection of IFN-g production by quantitative reverse transcription real-time PCR with the light cycler system
The feasibility of quantitative real-time PCR (QRT-PCR) for the analysis of Ag-specific T-cell responses in both PBMCs and tumor tissues has been validated. 20 QRT-PCR was performed as described earlier. 21 Analyses of IFN-g mRNA transcripts detectable in epitope-stimulated PBMCs were compared with IFN-g mRNA transcripts detectable in control samples. Optimization assays in the system of CMV-specific CTL responses identified a mean ratio of 0.96 (range: 0.65-1.11) with a 95% confidence interval of 0.96±0.09 and a s.d. of 0.13. The cutoff ratio was estimated by adding the mean to five s.d. that equaled 1.61. To minimize the possibility of false-positive results, we considered a minimum of twofold increase of the IFN-g transcript ratio as evidence of epitope-specific reactivity in accordance with results published by others. 2, 20 Statistical analysis Relapse-free survival curves were generated by the KaplanMeier method and verified by the log-rank (Cox-Mantel) test with the WinStat program (http://www.winstat.com). Furthermore, Fisher's exact test was applied as secondary significance testing (http://www.langsrud.com/fisher.htm). Differences were considered significant when Po0.05 was obtained.
Results
New HLA class I epitopes from the MUC1 Ag predicted by computer analysis are recognized by specific CTLs from patients after allo-SCT We tried to define new MUC1 peptides from HLA restrictions other than HLA-A*0201 to broaden the repertoire for screening and exploring the possibility that MUC1 might be a target of T-cell responses post allo-SCT. New MUC1 peptides binding to HLA-A*6801, HLA-B*0702 and HLA-B*4402 predicted by computer analysis using SYFPEITHI were synthesized (see Table 2 ).
All patients with matching HLA types were screened for a T-cell response toward the predicted peptides.
With this approach, we were able to detect CD8 þ T-cell responses against new HLA class I epitopes from the MUC1 Ag restricted to HLA-A*6801, B*0702 and B*4402 in a total of seven patients by intracellular cytokine staining directly ex vivo (see Figure 1 and Table 3 ).
CTLs specific for predicted peptides can be induced in healthy donors by repetitive stimulation with peptide-pulsed APCs One important point to ascertain the predicted MUC1-peptides as T-cell epitopes was by showing a specific induction of T cells in healthy donors who were tested negative for predicted MUC1 peptides in experiments performed ex vivo. Only peptides that were recognized in patients after allo-SCT were chosen for CTL induction. ALL: B-precursor ALL: failed CR within 4 weeks from starting induction therapy, WBC430 000/ml, pre-B-/t(4;11)/ALL1-AF4+ ALL. Early T cell or mature T-ALL: complex aberrant karyotype (X3 aberrations and at least one structural aberration) t(9;22)/BCR-ABL+ ALL. MM: at least one poor prognostic factor such as high b2-microglobulin, complex cytogenetics, no chemosensitivity at the time of allografting or relapse after prior autologous PBSCT.
Standard risk disease:
AML: age o50 years, Karnofsky score 460%, CD34 À phenotype, MDR1 À phenotype, WBCo30 000/ml, no antecedent hematologic disorder or prior chemo/radiotherapy. ALL: B-precursor ALL: CR on day 26 (after induction I), WBCo30 000/ml, no pre-B-/t(4;11)/ALL1-AF4+ ALL or t(9;22)/BCR-ABL+ ALL and thymic T-ALL. MM: CR or VGPR after induction chemotherapy without poor cytogenetic risk. þ T cells with peptide-loaded DC expressing other HLA types. Here, any induction of CTL responses by the TAA -peptides was not observed (data not shown). To prove endogenous Ag processing, a cell line containing 0.86% B44/ TEAASRYNL-specific CTL was stimulated with HLAmatched cells from a breast cancer expressing high levels of MUC1. A specific IFN-g production could be detected in half of the peptide-specific CTLs (0.47% of the CD8 þ ). The IFN-g production could be blocked with the MHC class I Ab W6/32 (see Supplementary Figure 1d ). This indicates the capability of the generated CTLs to recognize endogenously processed Ag through the MHC class I pathway.
Screening of CTL responses to tumor-associated Ags post allo-SCT We screened 28 patients post allo-SCT for spontaneous emergence of the CD8 þ T-cell responses to the known peptide epitopes from WT1, proteinase-3 as well as MUC1, in addition to the newly predicted peptides by flow cytometry (multimer staining and intracellular cytokine staining) and QRT-PCR after stimulation. Whenever possible, we applied all of these tests with IFN-g assay as mandatory to get information about the function of the specific CTLs.
A TAA-specific CTL response could be detected among 13/28 patients post allo-SCT.
In detail, patient no. 19 who received an allo-SCT for progressive MM showed a significant population of MUC1-specific T cells directed to the B44/TEAASRYNL peptide on day þ 672 (Figure 1a ). MUC1-specific cells were detected for the first time 1 week after donor lymphocyte infusion (DLI).
Another patient (no. 8) who showed a MUC1-specific response to the A2/STAPPVHNV peptide at day þ 471 (Figure 2b ) maintained the T-cell reactivity to MUC1 on day þ 1035, but interestingly a shift of specificity was observed. Now, the MUC1 T-cell response was directed to the DVTSAPDNK peptide presented by HLA-A*6801 (Figure 1b) .
MUC1-specific T-cell responses after allo-SCT targeting multiple HLA restrictions were found in patient nos. 18 and 21. Patient no. 18 showed both A2/STAPPVHNV-and B7/VPGWGIALL-specific IFN-g production detectable by intracellular cytokine staining on day þ 522 (Figure 1c ). This patient was in CR at the time of analysis. The same phenomenon was observed in patient no. 21 in whom A2/ STAPPVHNV-and B7/VPGWGIALL-specific CTL were detectable 347 days after transplantation. This patient unfortunately died while still in CR from other causes not related to the underlying disease. 
Abbreviations: HD ¼ healthy donor; ND ¼ not done. *These peptides were predicted de novo in this study by the use of the SYFPEITHI algorithm. The peptides shown in bold letters and in italics were demonstrated to be immune relevant in this study.
One of the patients (no. 26, see Figure 1d ) showed a very interesting immune phenomenon. T cells directed against the MUC1 B7/VPGWGIALL peptide were detected on day þ 15. This MUC1-specific response switched to the B7/ DPSTDYYQEL peptide on day þ 64 and disappeared after the patient received corticosteroids (2 mg per kg body weight) from day þ 134 onwards. This patient unfortunately relapsed on day þ 175 with persistent loss of the former CTL response.
In patient no. 11, we could detect A2/STAPPVHNVspecific CTLs on day þ 87 by both multimer staining and IFN-g QRT-PCR (Figure 2a) . TAA-specific CTLs contribute to the GVL effect M Kapp et al pre-existing immune response toward TAA. None of the donors showed specific IFN-g production after stimulation with the peptides, which were specifically recognized in the respective patients (date not shown).
In the case of three other patients, two with TAA-specific CTLs (patient nos. 3 and 25) and one without TAAdirected responses (patient no. 22) post allo-SCT, we had adequate PBMCs available pre-transplant to evaluate TAA-peptide reactivity by intracellular cytokine staining.
Here, we were also not able to detect TAA-specific CTLs pre-transplant (data not shown).
Relapse is significantly associated with the absence of TAA-specific T cells post allo-SCT The clinical outcome of patients is listed in Table 3 . Only 15% (2/13) of patients post allo-SCT with TAA-specific T cells relapsed in contrast to 60% (9/15) of patients without T cells specific for one of these Ags, namely MUC1, proteinase-3 or WT1 during the observation period (Table 3) .
There was a significant correlation between relapse of disease and absence of TAA-specific T-cell responses based on Fisher's exact test and Kaplan-Meier survival analysis (log-rank test (Cox-Mantel)) (Po0.05, see Figures 3a and b) . However, there was no significant correlation between the relapse rate and any of the known contributing factors, including the occurrence of acute GVHD or chronic GVHD, intensity of conditioning regimen or the individual risk of the underlying disease.
CD8
þ T-cell responses to CMV We routinely survey our patients' CMV status after allo-SCT to get an overview of their general immune recovery (Table 3) , as CMV control and CMV-specific immune recovery have been claimed to correlate with a better relapse-free survival among CMV-seropositive recipients. 22 Here, all patients who were CMV-seropositive pre-transplant (n ¼ 12) were subjected to CMV reactivation (PCR) and, whenever possible, also to CMV-specific CTL responses (flow cytometry), whereas CMV-seronegative patients were screened only for CMV infection. In this cohort, we did not observe a significant correlation between relapse-free survival and CMV control.
Discussion
The cure of hematological malignancies by allo-SCT shows the ability of the allo-immune response to recognize and destroy tumor cells. 23, 24 In the autologous setting, disease relapse is the main cause of death as compared with those who received allo-SCT. 25, 26 Better tumor control in allo-SCT is attributed to the expansion of residual donor T cells that mediate both GVL effects as well as GVHD. These effects are well observed after stem cell manipulation, whereby T-cell depletion leads to a reduced risk for GVHD, but inversely to an increased relapse rate. 27, 28 So far, there is scanty information pertaining to defined target structures of the GVL effect with only two different types of tumor Ags being distinguished, namely tumor-specific Ags and TAA. 29 With the discovery and cloning of MAGE-1 as the first TAA specifically recognized by T cells, 30 it has paved the fundamental and essential step toward a novel immunotherapy in malignant diseases. Clinical studies showed that therapy based on the expansion of TAA-specific T cells is beneficial to patients. 9,31,32 Rezvani et al. 2 described a potential relationship between WT1 and proteinase-3-specific CTL responses and GVL reaction. Here, a switch of the central memory cells in healthy donors to terminal differentiated effector cells in allogeneic stem cell recipients has implicated an ongoing GVL effect. 2 Inversely, loss of WT1-specific CD8 þ T-cell responses could be associated with the reappearance of WT1 transcripts indicating a relapse in allografted patients. 5 In our study, we analyzed the immunogenicity of the predicted peptides in a cohort of stem cell recipients as well as among healthy donors on the basis of the hypothesis that stem cell recipients may have an activated T-cell response Fisher's exact test (b) (http://www.langsrud.com/fisher.htm) were performed to evaluate whether there is a significant relation between TAA-specific CTL responses after allo-SCT and relapse.
TAA-specific CTLs contribute to the GVL effect M Kapp et al to TAA either in the form of GVL or GVHD reactions. In general, a CTL response required the recognition of MHC class I T-cell epitopes and the definition of such peptides binding to different HLA restriction elements. This is mandatory for the monitoring and possible immunotherapeutic strategies. We are able to screen the protein sequences by MHC binding algorithms that give rise to the prediction of candidate peptides for the respective HLA restriction using the 'reverse immunology' approach.
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Here, we adopted the theory from Scheibenbogen et al.
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in defining the predicted peptides, in their case from melanoma Ag tyrosinase, as T-cell epitopes that are immunogenic and form the targets of the clinically defined GVL effect. We are able to analyze T-cell responses directed to MUC1 in patients expressing MHC class I molecules other than HLA-A*0201. Peptides for the HLArestrictions A*6801, B*0702 and B*4402 were predicted by using the SYFPEITHI program (www.syfpeithi.de). Out of the 18 predicted peptides, we defined five new immunogenic MUC1 peptides restricted by these three different HLA molecules. With these newly defined MUC1 peptide epitopes, we were able to extend the analysis of CTL responses against TAA to a wider scope of transplant patients. In some cases, more than one peptide epitope could be evaluated in an individual patient. In contrast to Gu¨ckel et al., 34 we could not detect any specific CTL response against the TAA epitopes among the healthy blood donors directly ex vivo (data not shown). However, we could find TAA-specific CTLs directly ex vivo in allogeneic stem cell recipients. These CTLs were directed against new MUC1 peptides and the known epitopes from MUC1, WT1 and proteinase-3 1,2,10 ( Table 2 ). In addition, we managed to induce MUC1-specific CTL response for 3/5 of the new peptides in healthy donors by repetitive stimulation with peptide-loaded autologous DCs. Frequencies of MUC1-specific CTLs were between 0.20-1.22% of all CD3 þ /CD8 þ cells. Furthermore, we were able to show that HLA-matched tumor cells could activate a MUC1 peptide-specific CTL line (B*4402: TEAASRYNL). This tumor-specific T-cell response could be blocked by the MHC class I Ab W6/32, which further confirmed that the MUC1-specific CTL recognizes endogenously processed tumor Ag in a HLA class I-dependent manner. The HLA class I specificity could be counterchecked with negative control stimulations in an HLA context other than A*6801, B*0702 or B*4402.
In our study population, TAA-specific T-cell responses to different peptides could be detected in 13/28 patients post allo-SCT. As shown in three patients who acquired such TAA-specific CTL response (nos. 4, 25 and 26) , these immune responses were not detectable in the stem cell donor implicating an expansion of the antigen-specific CTLs response in the patient, consistent with a GVL effect. Moreover, these patients attained 99.6-100% donor chimerism denoting that such TAA-specific CTLs were of donor origin. Consistent with Rezvani et al., 2 HLA-A*0201-restricted T-cell responses against the Ags proteinase-3 and WT1 could be detected post allo-SCT for ALL and AML among our cohort of patients. In addition, we show for the first time that MUC1 CTL responses exist both in post allo-SCT AML and MM patients. Alloreactivity in the transplant setting may increase the probability of 'epitope spreading,' leading to the possibility that selfAgs such as the TAA used in this study become targets of the donor-derived CTL. Our data support the beneficial role of TAA-specific CTL responses after allo-SCT, which encompass a broad spectrum of hematological malignancies (AML, ALL, MM) and are not just limited to a single disease such as ALL. These target Ags already have been used for vaccination strategies in solid tumors (MUC1, WT1) 9, 35 and hematological malignancies (proteinase-3, WT1). [35] [36] [37] They may also play an important role as a target for T-cell therapy or vaccination approaches among allogeneic stem cell recipients.
In some patients with long-lasting CR, the TAA-specific T-cell response disappeared. Therefore, we hypothesize that it is because of a decrease in the antigenic stimulus in the post transplant remission period, leading to a drop of the TAA-specific CTL responses below the detection limits of our laboratory assays (see Table 3 ).
In contrast with those patients with an enduring remission, in one other patient the functional MUC1-specific CTL response that was detected earlier disappeared after steroid treatment for GVHD. This patient received 2 mg per kg body weight steroids and unfortunately relapsed shortly after prednisolone application with persistent loss of the TAA-specific CTL response. The other patients with concomitant GVHD and TAA-specific CTL responses also received immunosuppressive treatment, but none of them exceeded 1 mg/kg prednisolone, which to us is a critical limit for sustaining the function of Ag-specific CTL responses. Our previous experiences in the setting of CMV-specific CTL responses post allo-SCT have shown that steroid treatment above 1 mg/kg may abolish the functional CMV-specific immune responses resulting in CMV reactivation. 38 This case highlights the importance of a careful balance between immune suppression for GVHD treatment and the maintenance of antitumor immunity.
In our trial, patients with T-cell responses against TAA post allo-SCT showed a significantly better clinical outcome. Only 2/13 patients (15%; patient nos. 12 and 26) with TAA-specific CTLs relapsed as compared with 9/15 patients (60%) without these responses (Po0.05). There was no significant correlation between relapse-free survival and the occurrence of acute or chronic GVHD, which might be attributed to a relatively small cohort of patients, as these influences have been proven in larger studies or even in meta-analyses. 23 Despite the major issue of a limited number of patients, as compared with other trials in the field of specific immune recovery after allo-SCT, 1,5 28 patients (12 AML, 12 MM and 4 ALL) are relatively a large cohort even when taking into account the subgroups. In our cohort of 28 patients, the correlation between a TAA-specific T-cell response and relapse is strong enough to reach a statistical significance using two different statistical methods.
Another parameter that has been claimed to attribute a lower risk of relapse to patients after allo-SCT is a better general immune recovery. Nakamura et al. 22 suggested that the presence of CMV immunity could serve as a surrogate marker for determining the strength of the GVL effects in CMV-seropositive patients. However, in our cohort, we did not observe a significant correlation between a higher risk of disease relapse and CMV reactivation. mHA (for example, HA-1) are other probable target Ags after allo-SCT that may additionally account for GVL effects independent of GVHD. 39 However, allelic polymorphisms in HA-1 are a predictive parameter of GVHD in recipients of HLA identical stem cell transplants. 40 Therefore, the correlation of GVHD and HA-1 suggests that the GVL effects are mediated by other targets independent of GVHD and mHA.
In our study, relapse of the underlying disease was significantly correlated with a lack of TAA-specific CTL responses but not with the absence of acute or chronic GVHD. We have also analyzed the correlation of other known risk factors influencing relapse after allo-SCT, such as the intensity of a conditioning regimen and the intrinsic biological nature of the underlying disease. We could not detect any significant correlation that such risk factors contribute to disease relapse.
Therefore, we conclude that the CTLs targeting TAA might contribute to a specific GVL effect that is independent from GVHD and other known risk factors.
Furthermore, transfer of TAA-specific CTL or vaccination with peptide-pulsed DC could be used to improve GVL reactions. From our previous experience among patients with CMV reactivation post allo-SCT, a DC vaccination can be administered safely even in a HLA mismatch setting to induce protective immune responses against infectious diseases. 38 Hence, a vaccination strategy targeting these TAA seems to be an attractive and useful approach to improve antitumor control post allo-SCT.
Our study indicates that immune responses against TAA, such as WT1, proteinase-3 and MUC1, might play an important role in GVL reactions and disease control. Thus, these responses could be used for disease monitoring and as a prognostic factor for tumor control post transplant. TAA-specific CTL responses can be detected even in the absence of GVHD. Therefore, immunotherapy targeting TAA might be a promising approach to prevent relapse post allo-SCT. Currently, clinical trials using vaccination with donor-derived TAA-peptide-pulsed DCs are initiated at our center to evaluate the potential to induce a GVL effect in allo-SCT recipients.
